
Statins Beyond LDL-C: Pleiotropy, Special populations, & Why They Still Matter
About this episode
Let’s talk about statins. I know… boring, right? Most of us already know a lot about them. But thinking of statins only as cholesterol drugs misses the bigger picture.
In many ways, statins are best understood as anti-atherosclerotic therapies that modify plaque biology, vascular inflammation, and cardiovascular risk far beyond simple LDL reduction.
In this episode, we cover:
- Pleiotropic effects of statins beyond LDL-C lowering
- Choosing the right statin in special populations
- Why statins remain foundational therapy even in the era of newer lipid-lowering drugs
Whether you prescribe statins daily or want a deeper understanding of why they work so well, this episode revisits the science behind one of the most important therapies in preventive cardiology.
Bonus: Visual guide to help you navigate the episode.
Join the Learn at Pinnacle app to earn FREE CE Credit for listening to this episode!
Disclaimer: This podcast is intended for educational purposes for clinicians and healthcare professionals. It does not provide medical advice, establish a physician–patient relationship, or replace individualized clinical judgment. The opinions expressed are those of the creator and do not represent the views of any affiliated institutions or organizations.
Get every episode summarized
Each time LipidCurious publishes, we email you a written briefing from the transcript — the topics, who appeared, and any specific claims, with the ad reads skipped.
Email me new episodesFree for 3 shows. No card needed.
Hosts & guests
No transcript yet
This episode has not been transcribed. Request it and it moves to the front of the queue.
More episodes
More from LipidCurious

A Simple 3-Step Way to Approach the 2026 Multisociety Dyslipidemia (or Any) Guid...
LipidCurious

LipidCurious Inspiration: Dr.Thomas Dayspring
LipidCurious

ASCVD Risk Stratification Series (Part 3/3): LDL-C Targets, Treatment Options &...
LipidCurious

ASCVD Risk Stratification Series (Part 2/3): Using Risk Scores & Enhancers Witho...
LipidCurious